Drug Profile
Research programme: oncolytic virus therapies - Transgene/Randox
Alternative Names: Anticancer virus therapies - Randox/Transgene; Anticancer virus therapies - Transgene/Randox; Oncolytic immunotherapies - Randox/Transgene; Oncolytic immunotherapies - Transgene/Randox; Oncolytic virotherapies - Randox/Transgene; Oncolytic virotherapies - Transgene/RandoxLatest Information Update: 14 Jun 2023
Price :
$50
*
At a glance
- Originator Randox; Transgene
- Class Antineoplastics; Oncolytic viruses
- Mechanism of Action Immunostimulants; Programmed cell death-1 ligand-1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 14 Apr 2023 Research programme: oncolytic virus therapies - Transgene/Randox is still in preclinical trials for Solid tumors in France (IV)
- 14 Apr 2023 Research programme: oncolytic virus therapies - Transgene/Randox is still in preclinical trials for Solid tumors in United Kingdom (IV)
- 14 Apr 2023 Pharmacodynamics data from a preclinical trial in Solid tumors presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)